Literature DB >> 12017291

Enhanced casein kinase II (CK II) activity in human lung tumours.

Ilhan Yaylim1, Turgay Isbir.   

Abstract

BACKGROUND: Casein kinase II (CK II) is expressed at a higher level in lung tumours when compared to the corresponding non-neoplastic lung tissue.
MATERIALS AND METHODS: The aim of the present study was to evaluate the activity of CK II both in neoplastic and non-neoplastic human lung tissue by using a synthetic peptide with Arg-Arg-Arg-Asp-Asp-Asp-Ser-Asp-Asp-Asp (RRRDDDSDDD) sequence. One unit of CK II activity is defined as the amount catalysing the transfer of 1 pmol 32P into the substrate within 1 minute at 37 degrees C.
RESULTS: The activities measured for the neoplastic and non-neoplastic tissues were 1250-1500 U/mg protein and 100-500 U/mg protein, respectively. According to these results, the maximum activity observed in the lung carcinomas was 2 to 3-fold higher than the lung tumour specimens when compared to the non-neoplastic lung tissue. The activity range of CK II was between 500-1500 U mg protein.
CONCLUSION: Our results suggest that CK II plays an important role in cellular proliferation and the mechanism of its activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12017291

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

Review 1.  Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Authors:  Christian Borgo; Claudio D'Amore; Stefania Sarno; Mauro Salvi; Maria Ruzzene
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

2.  Mining CK2 in cancer.

Authors:  Charina E Ortega; Yoshua Seidner; Isabel Dominguez
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

3.  Association of protein kinase CK2 inhibition with cellular radiosensitivity of non-small cell lung cancer.

Authors:  Qianwen Li; Ke Li; Tianyang Yang; Sheng Zhang; Yu Zhou; Zhenyu Li; Jinrong Xiong; Fangzheng Zhou; Xiaoshu Zhou; Li Liu; Rui Meng; Gang Wu
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

Review 4.  CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.

Authors:  Melissa M J Chua; Charina E Ortega; Ayesha Sheikh; Migi Lee; Hussein Abdul-Rassoul; Kevan L Hartshorn; Isabel Dominguez
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-28

5.  Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.

Authors:  Ke Li; Fangzheng Zhou; Yu Zhou; Sheng Zhang; Qianwen Li; Zhenyu Li; Li Liu; Gang Wu; Rui Meng
Journal:  Int J Mol Med       Date:  2019-05-30       Impact factor: 4.101

Review 6.  Building Cell Selectivity into CPP-Mediated Strategies.

Authors:  Irene Martín; Meritxell Teixidó; Ernest Giralt
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.